重新定义重症哮喘缓解:区分疾病活动与损伤的概念框架
本文提出一个 refined 框架,将重症哮喘缓解理解为可改变的疾病活动与不可逆重塑及共病相关因素的区分,并引入「高危哮喘」概念。文章梳理四个病理生理域及其时间演变,提出基于域的策略,将靶向治疗与机制关联,以支持更个性化决策。
要点
- 现有缓解定义依赖症状、肺功能与激素减量,只能回顾性判断,未反映驱动疾病进展的机制与病理。
- 提出区分可改变的疾病活动与不可逆重塑及共病相关因素,以避免对不可逆疾病的过度治疗。
- 「高危哮喘」以高疾病活动和免疫失调为特征,及时干预或可预防不可逆损伤并支持长期疾病修饰。
核心结论
- 缓解不应仅视为症状消失,而应定义为疾病生物学的稳定化。
- 区分可改变的疾病活动与不可逆损伤有助于早期、疾病修饰性干预并避免过度治疗。
研究设计与样本
- 本文为 Lancet Respir Med 的 Series 论文,属概念框架类文章,未报告原始研究样本量或检索范围。
主要发现
- 现有缓解定义聚焦症状控制、肺功能和皮质类固醇减少,缺乏精确性且只能回顾性确定。
- 症状、肺功能损害和急性发作可由不同且重叠的机制引起,临床评估需仔细归因。
- 提出四个关键病理生理域:气道高反应性、免疫高反应性、免疫重塑和结构重塑,并描述其时间演变与治疗反应含义。
关键数值与推荐
- 提出「高危哮喘」为高疾病活动与免疫失调的关键阶段,及时干预可能预防不可逆气道和肺外损伤。
- 提出基于域的评估与干预策略,将靶向治疗与 underlying 机制关联。
临床怎么用
- 临床评估中应仔细归因症状、肺功能损害和急性发作背后的不同机制。
- 对高危哮喘患者考虑早期靶向干预以预防不可逆损伤,同时避免对不可逆疾病的过度治疗。
- 基于病理生理域选择靶向治疗,支持更个性化的治疗决策。
局限性
- 本文为概念框架,未报告原始研究数据、样本量或验证性结果。
- 框架的临床适用性和长期结局影响尚需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remission is emerging as a feasible treatment goal in moderate-to-severe asthma, driven by the success of biologic therapies in controlling inflammation and reducing exacerbations. Yet current definitions of remission-focused on symptom control, lung function, and corticosteroid reduction-lack precision, can only be ascertained retrospectively, and do not reflect the underlying mechanisms and pathology that drive disease progression. This gap limits the clinical applicability of these definitions and might obscure opportunities for early, disease-modifying intervention. In this Series paper, we propose a refined framework for understanding and reaching remission, centred on distinguishing modifiable disease activity from irreversible remodelling and comorbidity-related factors that contribute to disease burden. We introduce the concept of at-risk asthma as a crucial phase characterised by high disease activity and immune dysregulation, in which timely intervention might prevent irreversible airway and extrapulmonary damage and support long-term disease modification. We examine how symptoms, lung function impairment, and exacerbations can arise from distinct and overlapping mechanisms, underscoring the need for careful attribution in clinical assessment. We also outline four key pathophysiological domains-airway hyper-responsiveness, immune hyper-responsiveness, immune remodelling, and structural remodelling-and describe their temporal evolution and implications for treatment responsiveness. Finally, we present a domain-based strategy for assessment and intervention, linking targeted therapies to underlying mechanisms. This approach supports more personalised treatment decisions and redefines remission, not simply as the absence of symptoms, but as stabilisation of disease biology. As the field advances towards earlier intervention and more tailored application of biologics in at-risk asthma, such a framework could be essential to improve long-term outcomes and prevent overtreatment of irreversible disease.
引用
- Porsbjerg C, Rupani H, Brannan JD, et al. Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage. Lancet Respir Med. 2025. PMID: 41038212. doi:10.1016/S2213-2600(25)00299-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。